Nasdaq

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
Benzinga.com

Infinity Pharmaceuticals Says Second Proxy Advisory Firm Recommends Shareholders To Approve Proposed Merger

Infinity Pharmaceuticals Inc (NASDAQ:INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the Head and Neck (SCCHN). The adaptive design of the MARIO-8 study ...
Mining Weekly

Updated scoping study for Infinity’s Spain project proves positive

Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...
ascopubs.org

Neoadjuvant and adjuvant iruplinalkib in resectable ALK or ROS1 fusion-positive, non-small cell lung cancer (NSCLC): The preliminary results of the single-arm, exploratory Neo ...

Value of tumor mutational burden as a prognostic factor in patients with non-small cell lung carcinoma.